Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
Home About Us Product Pipeline News Investors Contacts Careers


Recent Press Releases Archives

Recent Press Releases

2024 News Releases

Mar. 20, 2024 - Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Feb. 29, 2024 - Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results

Feb. 27, 2024 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Feb. 22, 2024 - Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference

Feb. 15, 2024 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

Feb. 13, 2024 - Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

Jan. 11, 2024 - Puma Biotechnology to Present at B. Riley Securities 4 th Annual Oncology Conference

Corporate Fact Sheet

Puma Biotechnology, Inc.

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax